These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9041207)

  • 41. Clinical practice guidelines for assessment and management of iron deficiency.
    Madore F; White CT; Foley RN; Barrett BJ; Moist LM; Klarenbach SW; Culleton BF; Tonelli M; Manns BJ;
    Kidney Int Suppl; 2008 Aug; (110):S7-S11. PubMed ID: 18668119
    [No Abstract]   [Full Text] [Related]  

  • 42. [Helicobacter pylori does not contribute to iron deficiency in hemodialysis patients].
    López T; Almirall J; Calvet X; Quesada M; Sanfeliú I; Segura F; García M
    Nefrologia; 2006; 26(6):673-8. PubMed ID: 17227244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
    Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
    Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effects of iron therapy in renal failure patients on hemodialysis.
    Fishbane S; Mittal SK; Maesaka JK
    Kidney Int Suppl; 1999 Mar; 69():S67-70. PubMed ID: 10084289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
    Wingard RL; Parker RA; Ismail N; Hakim RM
    Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis of iron deficiency in dialysis patients.
    Phelps KR
    Am J Kidney Dis; 1996 May; 27(5):762-4. PubMed ID: 8629643
    [No Abstract]   [Full Text] [Related]  

  • 49. The Content of Reticulocyte Hemoglobin and Serum Concentration of the Soluble Transferrin Receptor for Diagnostics of Anemia in Chronically Hemodialyzed Patients.
    Kurzawa T; Owczarek A; Strzelczyk JK; Gołąbek K; Wiczkowski A
    Adv Clin Exp Med; 2016; 25(3):425-31. PubMed ID: 27629729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
    Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
    Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
    Besarab A; Dalton CL
    Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does iron cause bacterial infections in patients with end stage renal disease?
    Cieri E
    ANNA J; 1999 Dec; 26(6):591-6. PubMed ID: 10876474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of intravenous iron therapy on novel markers of iron deficiency.
    Chinnappa S; Bhandari S
    Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.
    Kalantar-Zadeh K; Höffken B; Wünsch H; Fink H; Kleiner M; Luft FC
    Am J Kidney Dis; 1995 Aug; 26(2):292-9. PubMed ID: 7645533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients.
    Kooistra MP; Marx JJ
    Nephrol Dial Transplant; 1998 Oct; 13(10):2578-82. PubMed ID: 9794563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategies for iron supplementation: oral versus intravenous.
    Macdougall IC
    Kidney Int Suppl; 1999 Mar; 69():S61-6. PubMed ID: 10084288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The treatment of anemia in peritoneal dialysis patients.
    Lacson E; Diaz-Buxo JA
    Clin Nephrol; 2001 Dec; 56(6):415-27. PubMed ID: 11770793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.